Mettler-Toledo International Inc. (MTD) Earnings Call Transcript & Summary

Good morning to everyone in the room and on the webcast. Thank you for joining us today. Before we turn to our Q&A session, I'd like to provide a brief update on Mettler-Toledo, our business, our strategy, touch a few key themes we see unfolding in our industry today, but also share with you why we are so optimistic about our long-term growth opportunities we see for our business. Before we get started, please note our disclosure regarding forward-looking statements in the slides. For those of you who know us well, you've probably seen this slide before, it is 1 that our company is very proud of. We have a long-term track record of strong financial performance, and we are looking forward to continuing to build on this track record. And this performance has been built with several important differentiators for our business. First, we are primarily focused on driving organic growth across the many highly fragmented markets we participate in. Second, to drive this growth, we have internally developed many important strategic growth programs that we continuously improve. These programs are well ingrained in the organization and also help us focus on the most attractive opportunities in the market. And then finally, we have a unique culture at Mettler-Toledo that is squarely focused on our customers, on innovation, collaboration, continuous improvement and agility. This enables us to support our customers to make new developments, enhance productivity and improve quality. We lead the industry in innovation and by leveraging our unique growth strategies and culture of execution, we have consistently driven incremental market share gains and robust earnings growth. Now let me share some details about our product offering, and I will start with our laboratory products, which represent approximately 57% of our total sales. We provide scientists and engineers with the most frequently used instruments found in a variety of laboratory environments. This slide highlights our laboratory offering that helps customers accelerate their R&D efforts. These customers require a high degree of precision and flexibility, which we support with our high-end balances, analytical instruments, pipettes and automated chemistry solutions. We are well known for our innovation, quality and deep application know-how. R&D customers also increasingly seek productivity and automated workflows and which we facilitate with our LabX instrument control and data management software as well as automation solutions to increase throughput and simplify workflows. LabX provides full data integrity and complaints and is unique in the marketplace. Our laboratory instruments are also very important in QA and QC labs. These instruments include balances and a wide range of analytical instruments. Our strong presence in the lab is evident in that we can provide approximately 40% of the bench instruments typically used in an analytical quality control app and can connect them also with our LabX software. The final piece of our lab business is process analytics, which is focused on continuous in-line measurement of various parameters in process control, including TOC, conductivity, pH, oxygen, CO2 and pressure sensors that are connected with our transmitters. Biopharma is an important market for this business as well as chemical industry in the fast-growing segments like semiconductor manufacturing. This business features our intelligent sensor management technology, which are intelligent, digital and analytical sensors that bring predictive diagnostics and other valuable features for reliable, consistent process control. This next slide is an overview of our industrial products, which represent approximately 40% of our total sales. The largest portion of our industrial its core industrial business, which represents approximately 25% of our total sales. Here, we provide solutions that facilitate process control for many of the same customers as of all lab products. life sciences, food, chemical and many others, but in their production environment. Our product offering includes scales, terminals, software, weigh modules and logistics solutions and our business mix has shifted over the years to support our customers' desire for automation and seamless integration in their factory information systems. We also provide unique solutions for high-speed precision weighing or applications in hazardous and hygienic areas. The other portion of our industrial business is product inspection, which represents about 15% of our total sales. In this business, we sell a variety of instruments primarily to packaged food manufacturers, but also to customers in the pharma and cosmetic industry to help them detect physical contaminants or prevent over and under filling of their products. This is a critical end-of-line process that ensures brand protection, high quality and increased productivity. In addition to our inspection instruments, we also offer our product software, which is a complete quality inspection data management system that delivers full digital management of product inspection equipment for real-time monitoring and food safety compliance. Lastly, we also provide a broad range of services that are very important to our customers to maintain reliable readings for our instruments and uptime in the production environment. Our global service network of over 3,000 is an important competitive advantage. We have seen steady increases in customer satisfaction over the years and have earned exceptionally high Net Promoter Scores from our customers. Service remains a very important strategic growth opportunity for our company due to the opportunities to penetrate our installed base, our expanded solutions offering and our other competitive advantages. Our robust portfolio of innovative products and service solutions has helped us build a very strong brand and several important competitive advantages. First, we are the market leader in a significant majority of our businesses with a market share of on average of 25% to 30%, and the highly fragmented nature of these markets provide significant room for additional market share expansion. Secondly, to identify and capture the market opportunities in these fragmented markets, we have built a sales team of about 3,000 specialists with deep application know-how. Our spinnaker sales and marketing program is very unique and allows us to identify and direct our sales specialists to the best growth opportunities. Third, we have an installed base of instruments of over $16 billion worldwide. We support this installed base with the largest global service organization of our direct competitors and this installed base is also an important source of customer upgrades and replacement demand. And lastly, we have a global supply chain and manufacturing footprint that enhances our cost leadership. We serve very attractive markets and estimate that over 70% of our sales are to life sciences, food manufacturers and chemical companies. Over the years, this mix has grown as our spinnaker sales and marketing program has become increasingly sophisticated in guiding our sales team to the most attractive market opportunities. The outlook for these markets remain very attractive over the long term as they seek solutions to help improve productivity in both the laboratory environment and also in the production environment. Additionally, customers are increasingly looking for solutions that help them with regulatory compliance and data integrity as well as higher levels of accuracy and reusability. The breadth of our laboratory products offering means that we can also provide seamless workflows with audit proof data integrity with our LabX software offering. Now I'd like to shift our growth strategies and how we leverage our strong competitive advantages and favorable market trends to capture market share and drive growth. First, diversity of our business and fragmented customers means we need a set of sophisticated tools and analytics to identify the most attractive and profitable growth opportunities for our field sales team to target. Spinnaker is a collection of sales, service and marketing initiatives and processes we use to drive sales growth and improve profitability. As mentioned, we have a tremendous opportunity to gain market share in our highly fragmented markets. A key element of spinnaker is to ensure we effectively optimize our field sales team, so they are focused on capturing the most attractive growth opportunities and selling to new customers and cross-selling with existing accounts. In addition to generating leads through our various marketing activities, our topK program provides our field teams with tailored and actionable investment alerts about specific sales opportunities that are generated by proprietary data analytics and deep learning software solutions leveraging external databases and our own internal databases. These alerts are qualified and prioritized, so our teams are guided to the most attractive opportunities in underpenetrated or hot segments in the market. We have further improved these alerts over the past year providing instant alerts to teams and dynamic qualification and feedback loops, helping them to effectively increase our time with accounts that are not yet our customers. Spinnaker also supports our cross-selling activities across divisions, utilizing insights from service technicians and other sources to feed our sales engine. As part of our continuous improvement process, we periodically launch a new wave of spinnaker that builds on previous waves and initiatives. We are currently launching our sixth wave, which will fully enhance customers' experience and leverage new possibilities offered by the digitalization of processes. Another important growth opportunity is our service business, which represents more than 20% of our sales. Our global sales -- our global service footprint is the largest of our direct competitors, and we have an important opportunity to further expand the proportion of our installed base that we service today. We estimate the service revenue opportunity of our installed base of instruments approximately $3 billion, and we are highly focused on further penetrating this opportunity. Selling services at the point of new product sales is an important growth opportunity for us and through improved training and optimization and order catching service growth to the new product growths, we have seen increased uptake rates for service contracts. We are also focused on penetrating our installed base through sophisticated data analytics and continue to see opportunities to further optimize our service processes to enhance customer experience, increase productivity and improve our people development. Our technology leadership is another important growth driver for our business. We lead our industry in innovation, and this helps accelerate replacement cycles, support market share gains and maintain our price premium in the marketplace. On this slide, you will see 2 examples of recent innovations for our lab customers. On the left, you see our next generation of digital process analytics sensors we released last year. Our intelligent sensor management ISM technology has been a key differentiator for process analytics over the past decade, and we have recently upgraded our entire ISM portfolio to provide full audit trail readiness, which is critical for pharma compliance as well as significantly enhanced sensor diagnostics and increased temperature range for a broad range, for broad coverage in demanding chemical applications. On the right, we feature our new DSC 5+ Thermal Analysis instrument that is the first instrument that is capable of switching between 2 different measurement modes. It also features a high-capacity robot that allows our customers to perform more experiments in a shorter time with fewer resources. It is a great addition to our portfolio and helps us to win with customers like those in the lithium-ion battery segment. On this slide, we highlight 2 other examples of recent industrial product launches. Our PHD smart floor scales, our new series of hygienic scales for customers in the pharma and food markets. It is an ultra-low profile scale that has a smart digital load cell, and it's easy to clean and move and provide industry-leading digital capabilities. On the right, you can see our new X2 series of actual inspection machines for small packaged food and pharmaceutical customers that detect hard-to-find physical contaminants such as glass and bone fragments and helps us cover a wider range of the market at many different price points. So overall, our R&D investments continue to provide a product portfolio that is stronger than ever and supports our growth and margin expansion initiatives, and we have accelerated certain innovation investments to capture growth opportunities. We continue to see increased demand for automation, digitalization and compliance, and we have several important new lab and industrial product launches later this year that directly address our customer needs in these areas. With no one product launch -- while [ no one ] product lunch is material to our results overall, given the significant diversity of our business, combined, they are a powerful contributor to our market share and margin expansion strategy. I'd now like to share with you an update on our margin expansion initiatives. We have an excellent track record of expanding our margins, and we remain confident in our ability to continue to expand our margins in the future. The largest driver to margin expansion comes from our organic sales growth. Additionally, our business mix has improved over time as our fastest-growing products are also our highest margin products. And we also aim to expand our sales of services and consumables, which are also higher margin. We continue to be successful with our global pricing program, which helps us to capture value in the marketplace from our innovations. Our SternDrive program is another important driver to margin expansions and helped us reduce our material costs and increase our manufacturing and back-office productivity through the diligent execution of hundreds of small improvement projects at any 1 time. We launched our third wave of SternDrive at the end of last year, and this wave was on top of our cost reduction programs and has a focus on smart automation in our facilities. Most of our manufacturing facilities have a product offering that is rather lower volume with high mix, which in the past did not lend itself to automation. But today, low-cost cobots and robots that are easy to program and install are making their way into our production facilities, providing productivity gains with the fast payback periods. Finally, while we are fundamentally focused on organic sales growth, we will also continue to look to expand our product offering through small- to medium-sized bolt-on acquisitions that can help expand our technology leadership, product offering and channel reach. We are typically looking to acquire businesses and technologies that are a good complement to our existing product offering and can leverage our global manufacturing and direct sales footprint. Now let me share a few thoughts on the business environment. 2023 was a particularly challenging year after exceptional growth over the past few years. Market demand declined in our core segments of life sciences, food manufacturing and chemicals, which combined represent more than 70% of our revenues. Life Sciences was particularly down after very strong growth during the pandemic. Additionally, China comprise about 20% of our sales and had a strong start to the year after emerging from their prolonged COVID lockdowns. However, this momentum was short-lived and reduced market demand and the deteriorating economic environment led to an unprecedented decline in the second half of 2023. I'd like to also share with you additional details about our fourth quarter results that we disclosed late last week. As you have read, our fourth quarter sales and EPS will be below our previously issued guidance due to the unexpected issues with a new third-party logistics provider in Europe. As a backdrop, we have initiated a stack-up process of transitioning to a new operator for our logistics hub in Europe in 2022. After extensive tests in the first quarter of 2023, we started to gradually transition to the new distribution center. And by the end of the third quarter, had transitioned approximately 70% of our products. During the fourth quarter, we transitioned our remaining products to the new provider, but they were not able to handle this increased volume as anticipated, due to process flow initiatives -- inefficiencies that resulted in shipping delays. Now while we are extremely disappointed with this development, we are working very closely with our new provider including their executive team. Our backlog in Q4 was higher than expected by a similar amount of our Q4 sales decline or shortfall -- by a similar amount of our Q4 sales shortfall and anticipate to have largely recovered these sales in Q1. Relatively to our fourth quarter results, the disruption disproportionately impacted our laboratory results and our results in Europe. China came in-line with our expectations, while Europe was significantly worse and the Americas was also lower than expected. We were pleased with the continued momentum of our service business, which came in as expected. Industrial came in as expected, while laboratory and retail were below our expectations. We currently expect adjusted EPS to decline approximately 23% year-over-year in Q4, which is below our prior guidance of a 12% to 13% decline. While we expect to benefit from the delayed sales in the first quarter of 2024, please keep in mind, we continue to face challenging year-over-year ago comparisons. We have not yet provided any updates to our 2024 guidance, and we'll provide further detail in early February when we report our fourth quarter results. Now while market conditions are currently softer, we remain focused on the factors we can control. We are confident that our business will emerge stronger from the current downturns due to important investments in growth that I just shared with you. Additionally, we see several important growth opportunities across the markets we serve driven by reshoring and the needs for automation and digitalization. We also see opportunities with new pharmaceutical modalities as well as investments in alternative energy and mobility, semiconductors and sustainable materials. Our ability to demonstrate resilience and agility during challenging times is an important element of our DNA. We also continue to implement strategies with a good balance of initiatives focused on growth and operational excellence. We will continue to increase our focus on productivity and cost savings until we return to normalized growth. So let me summarize the key points from my presentation today. First, we have significant competitive advantages, including a strong product portfolio, highly sophisticated go-to-market strategies a great service organization and a highly collaborative global team. Our culture of innovation, collaboration, agility and continuous improvement makes tremendous difference and is a key competitive differentiator. Additionally, we remain focused on delivering outstanding customer experience. For example, we are strengthening our organization where we see more demand, such as within the service organization. We also continue to invest strongly into next-generation products and solutions as well as enhancing our best-in-class corporate programs like spinnaker to drive growth and capture market share and SternDrive to manage our costs effectively. This will help us to not only increase our competitiveness during our difficult market situation, but also puts us in an even more favorable position once the markets pick up again. And lastly, our growth strategies and culture of continuous improvement are important drivers of continued margin expansion over the medium term, which provides significant free cash flow that we return to shareholders through our share repurchase program. Now that concludes my comments, and thanks, everyone, for joining us today.

Awesome. Thank you, Patrick. So first up, I just wanted to dig into the 4Q pre-announcement and some of the logistics issues. You kind of walked through some of the high level, but can you dig a little bit deeper. Number one, how did this just come up so late in the quarter, I guess, at what point did you start to really realize this was a more bigger issue than you initially thought? And then alongside of that. Can you just talk about -- you mentioned the backlog still being intact. Can you just point out, would you have hit the 4Q number if it wasn't for this logistics issue? And then what is your confidence level in that as well?

Good. Very good question. So, as I said in my presentation, we had a very diligent process in place as we moved from our prior logistics provider to the new one. We started a process already in 2022. And in Q1, we started transitioning the IT system with very thorough testing. And then starting Q2, we also start transferring the product portfolio from the former logistics provider to the new logistic provider. That went very well until the end of Q3 when we had transferred about 70% of the portfolio. But as we transition the remaining product portfolio up to 100% in Q4, they have been faced with process inefficiency that then led actually to this buildup of backlog. Initially, we thought that they can get over this very quickly. We have constant calls with them, but it turned out that it really could work it down in Q4. Regardless, we are working very closely with them on resolving these issues as quickly as possible. We have our best logistics experts on site with them as well to make sure that we really can worked this down during Q1. As we said, this is -- from our perspective, is really a transitional situation that we -- most of that we can resolve in Q1. Regarding your question regarding the backlog size. As I said, the backlog increase is probably proportional to decline in sales that we have seen in Q4, right? So that's -- I would say, if you calculate out that increased backlog, our sales would've been within the range that we have guided.

Great. And then just alongside that 4Q update, you mentioned in the presentation that China was in line with your prior guidance. Europe was significantly impacted Americas was lower. Could you just clarify for that for us. Was that a comment just solely regarding this logistics issue? Or in terms of the Europe and the U.S. performance, was that in addition to the logistics performance relative to your expectations.

I'll let Shawn to give you more details on the numbers.

Okay. Thanks, Rachel. Maybe I'll give you a little bit of color by region, excluding the impact of the shipping delays. So as we said in the prepared remarks, China came in as expected. This is a global issue. So there was actually a little impact in China. So if you exclude the shipping delays in China, China would have come in actually slightly better. That's kind of the same for the Americas. The Americas would have come in slightly better, a little bit more impacted than China from the shipping delays. And then if we look at Europe, Europe was the most impacted out of the 3 regions. And it would have also been lower than expected. We did see some softness in food manufacturing in the quarter in Europe as well as, I think Germany came in a little bit lighter. Of course, we're still analyzing the results, and we'll provide more color when we update you in February. And then from a divisional perspective, I'd say the lab business, as we said in the prepared remarks, was the most impacted. If you exclude the shipping delays, it was generally in line with what we would have guided maybe like a point worth kind of thing. Industrial was in line overall, if you exclude the shipping delays, it was actually a little bit better than expected. We were very pleased with the results of the core industrial business in the quarter, while PI was a little bit worse than expected. And then retail was also very much impacted by the shipping delays. And if we exclude those effects, it would have been slightly lower than expected than our guidance.

Okay. That's helpful. And then I just wanted to talk about your conviction level and being able to catch up some of the slipped revenues in 1Q. First, could you just clarify for us, have you resolved this issue full year? Like what stage in the process are you kind of remediating some of this? And then how does that give you conviction in being able to catch up this in 1Q or maybe early 2Q?

Yes. So as I said, up to Q3 and obviously, at the moment where we have moved 70% of the portfolio, the operation was running fine. So as we moved the remaining part of the portfolio, which also had a bit more comprehensive mini finished processes in there, the new provider run into issues. And we quickly went there to understand what the issues are, train their people on the mini finish process, make sure that understand what they need to do to complete shipments, et cetera. And as of today, we are -- as I said, we are working very closely. We have our best logistics experts up there on site to help them really optimize the process flow, so my conviction that we can get this resolved through Q1 is very high. These are, again, we see this as transitional issues. It's a new setup. It's actually a complete new hub that they have built up with a lot of new automation capabilities. And they have demonstrated throughout the quarter on several days that they can manage the volume, but it has process issues on other days. They also face some issues with the Dutch custom system, which have been down a couple of days during the quarter, and that all pile them up to this incremental backlog. But as I said, our team is there. I'm in regular phone calls with the executive team, including their CEO, to make sure that we have all hands on deck to get this resolved.

Great. Helpful. And then I appreciate you said that you are not going to touch the 2024 guidance right now, kind of pointed us towards that 4Q earnings call. But I guess, how should we think about how you're going to approaching that guidance. Obviously, you had $60 million roughly of revenue slipped from 4Q to 1Q. You just mentioned your high conviction in being able to hit that. So should we read that as or it just helps you hit that 2024 guidance? Or is there something underneath in terms of demand or any incremental weakness that would lead you to not ultimately look that guide?

Yes. We appreciate the question. Of course, we're still analyzing the numbers to kind of put a number on it, it's probably is in the $55 million range or so could be in the higher 50s, we'll see. But in terms of 2024, we do fully expect this to be a benefit. But in terms of providing more insights on the market and guidance for 2024, we need to kind of continue to analyze the quarter and go through our normal process and be very happy to update you in February.

Understood. I had to try. Maybe just while we're kind of touching on 4Q here, budget flush has been a topic that's been coming up a lot this week, just given the results that you just walked us through, you hadn't really been expecting much of a normal budget flash. You mentioned that as of November, you hadn't seen it yet. So what's the latest update? Did you see any catch-up in spend during 4Q in those numbers?

In terms of budget flush, I think the quarter pretty much came in generally as we expected, excluding this one issue. And so that kind of includes really not much of a budget flush at all.

Helpful. And then I wanted to touch on the topic of long-term guidance. That's another area that's come up a lot in most of these conversations with tools companies. Mettler is guiding to at or above 6% local currency growth over that medium term. So just given the downturn that we're seeing right now, whether that's from macro or some of these cyclical issues, can you talk about your conviction level in hitting those long-term targets still?

Yes, sure. Look, we as a company, we have been around 5% growth company for a decade on average, and there have been up and downs during this time frame as well. But if you look at the shift in our product mix that we have today, we have actually a broader expansion now in the lab business. We have a broader footprint in the Life Science business. And if you look at the growth mid- to long-term growth opportunities in these underlying market segments. We see actually that we're very well positioned to capture market share gains in small gains as we did in the past on top of the underlying market gains. We see a clear need for digitalization and automation in the industrial markets, which we are fully focused on delivering that to our customers. And if you take all of that together, I think we are very well positioned to get to the 6% on the mid- to long-term. Of course, if the market will be suppressed for a very long time saying no growth in the market, we also not going to achieve the 6%. But if the market gets back to, let's say, 4% to 5% growth in -- with our incremental market share gains, we are very confident that we can get to the 6% plus.